Although other oncogenic and tumor-suppressive genes were predicted in silico, FOXP3 and EGFR were prioritized for their dual mechanistic relevance and translational potential as therapeutic markers in ovarian cancer. The gene discussed is FOXP3; the disease is neoplasm.